当前位置: X-MOL 学术Cell. Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Dual-target IL-12-containing nanoparticles enhance T cell functions for cancer immunotherapy.
Cellular Immunology ( IF 3.7 ) Pub Date : 2020-01-27 , DOI: 10.1016/j.cellimm.2020.104042
Jieyu Li 1 , Wansong Lin 2 , Huijing Chen 1 , Zhiping Xu 3 , Yunbin Ye 1 , Mingshui Chen 1
Affiliation  

Cytotoxic T lymphocytes (CTLs) play a major role in cancer immunotherapy. A potent tumor immunotherapy may not only require activation of anti-tumor effector cells but also rely on the use of cytokines to create a controlled environment for the development of anti-tumor T cells. In this study, we fabricated a dual-target immunonanoparticle, e.g. poly(d,l-lactide-co-glycolide) nanoparticle, by loading Interleukin-12 (IL-12) and modifying with CD8 and Glypican-3 antibodies on the surface. Our results demonstrate that the fabricated targeting immunonanoparticles bind specifically to the two target cells of interest, i.e. CD8+ T cells and HepG-2 cells via the antibody-antigen interactions and form T cell-HepG-2 cell clusters, which enhances the cytotoxicity of T cells. IL-12-containing dual-target immunonanoparticles delivered IL-12 specifically to CD8+ T cells, and favored the expansion, activation and cytotoxic activity of CD8+ T lymphocytes. These results suggest that dual-target IL-12-encapsulated nanoparticles are a promising platform for cancer immunotherapy.

中文翻译:

含IL-12的双重靶标纳米颗粒增强了T细胞功能,可用于癌症免疫治疗。

细胞毒性T淋巴细胞(CTL)在癌症免疫治疗中起主要作用。有效的肿瘤免疫疗法可能不仅需要激活抗肿瘤效应细胞,而且还需要依靠细胞因子来创造可控的环境,以开发抗肿瘤T细胞。在这项研究中,我们通过加载白介素12(IL-12)并用CD8和Glypican-3抗体修饰了双靶免疫纳米颗粒,例如聚(d,l-丙交酯-乙交酯)纳米颗粒。我们的结果表明,制备的靶向免疫纳米颗粒通过抗体-抗原相互作用特异性结合两个目标靶细胞,即CD8 + T细胞和HepG-2细胞,并形成T细胞-HepG-2细胞簇,从而增强了T的细胞毒性细胞。含IL-12的双靶免疫纳米颗粒将IL-12特异性地递送至CD8 + T细胞,并促进CD8 + T淋巴细胞的扩增,活化和细胞毒活性。这些结果表明,双靶IL-12包裹的纳米颗粒是癌症免疫疗法的有前途的平台。
更新日期:2020-01-27
down
wechat
bug